Oxaliplatin

Catalog No.S1224 Synonyms: L-OHP

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cleaved caspases and p-H2AX expression were detected by western blot in HCT116 cells (E) and HT29 cells (F). The cells were co-cultured with F. nucleatum or treated with CQ, and different concentrations of Oxaliplatin and 5-FU.

    Cell, 2017, 170(3):548-563.e16. Oxaliplatin purchased from Selleck.

    Immunocytochemical staining of SW620 (metastatic) cells after treatment with 10 uM oxaliplatin (F) or 10 uM ginsenosides 20(S)-Rg 3 (G) and negative staining (H). Cells demonstrated differential expression of histone H4.

    J Proteomics 2014 10.1016/j.jprot.2014.10.009. Oxaliplatin purchased from Selleck.

  • PDT and oxaliplatin combination treatment. A) Bar graph showing response (total volume of residual viale nodules normalized to no treatment control) to PDT treatmen (2.5 J/cm2), oxaliplatin treatment (10 μM), and PDT followed by oxaliplatin at the same doses. The dramatic enhancement, beyond the additive effect of the two modalities independently suggests there may be a synergistic interaction. B) A representative region from a culture stained with calcein AM and ethidium bromide following treatment with the PDT + oxaliplatin combination shows relatively small pockets of viable disease and many dead relative to untreated cultures.

    Optical Methods for Tumor Treatment and Detection 2013 10.1117/12.2010730. Oxaliplatin purchased from Selleck.

     

    Growth inhibitory effects of Oxaliplatin in human pancreatic cancer cells. MiaPaCa-2 cells were plated in triplicates into 48-well plates at a density of 10,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low-serum-containing medium (1% FBS) containing DMSO (control) or indicated doses of Oxaliplatin (Selleckchem). Cell viability 72 hours after treatment was determined by AlamarBlue assay (Invitrogen) according to manufacturer's instructions. Results are expressed as percentages of control, which was arbitrarily assigned 100% viability, and represented as the mean ± standard deviation (SD) of the tripicate wells. 

    2013 Dr. Edita Aksamitiene from Thomas Jefferson University. Oxaliplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 MYPDfZRwfG:6aXPpeJkhSXO|YYm= M1nFRVDjiJNzNkFCpO69VQ>? M{HLNVQ5yqCq NInDUXRKSzVyPUWuPOKhyrIEoECuOUDPxE1? NUfNc2ZjOjZ2N{S2PVM>
CaES-17 NVX1ZWtKS3m2b4TvfIlkcXS7IFHzd4F6 MnXFNQKBmzF4MNMg{txO MXW0POKhcA>? MkX4TWM2OD13LkZCpOKyyqByLkKg{txO NFfq[|MzPjR5NE[5Ny=>
SW480 MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIizXmk1QCCqwrC= NVLQT4ROUUN3ME2xMlg4KM7:TR?= MV2yOlI3QTd3OR?=
HCT116 NWXD[otNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHqwV2s1QCCqwrC= M{\mcWlEPTB;MUGuPFYh|ryP NYm3WoQ6OjZ{Nkm3OVk>
LoVo NILoT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLwN2xIPDhiaNMg NWTUZ5VPUUN3ME25OE45OyEQvF2= NWm2VI5kOjZ{Nkm3OVk>
SK-BR-3 NVP3b4VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fVTWlEPTB;M{GuNEDDuSByLkGg{txO MWCyOlIyOTV7MR?=
MCF-7 NELPRYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TjSmlEPTB;MUWuOEDDuSByLkOg{txO NFjVflIzPjJzMUW5NS=>
MDA-MB-231 NEGzVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLvTWM2OD1{Mz6xJOKyKDBwMTFOwG0> M3[ybVI3OjFzNUmx
HCT116 p53+/+ MVPGeY5kfGmxbjDBd5NigQ>? M3rW[|EwPSEQvF2= MkDLNlQwPDhiaB?= M3P4XYlv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= Mn3XNlYzODh3MkO=
LoVo  M1PTXmZ2dmO2aX;uJGF{e2G7 NX;4OXBWOS93IN88US=> M3HDdlI1NzR6IHi= M4\EbIlv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= MkPCNlYzODh3MkO=
SNU-398 NU[xXZZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrPTWM2OD14LkZCpOKyyqBzLkGg{txO MYOyOlE3ODR{OR?=
Hep-G2 NFjtSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq1dox{UUN3ME2xN{4yyqEEsdMgNU43KM7:TR?= NYfQc5ZnOjZzNkC0Nlk>
SNU-475 NV;IW|h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\qTWM2OO,:nkOwJO69VQ>? NUnreIZ2OjZzNkC0Nlk>
SNU-387 NU\JWFd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13ZdmlEPTB;MkZCpOKyyqB{Lkeg{txO NXT6fIpGOjZzNkC0Nlk>
HT29 NGSwTJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwOElCpOKyyqByLkKg{txO MorJNlYyPDh3OU[=
HCT116 NX3FfVA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzrOZVKSzVyPUCuOFHDqMLzwrCwMlAzKM7:TR?= NF7DTWczPjF2OEW5Oi=>
PA-1 MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIrJOXExNTJyIN88US=> NWPHN4pxOjRxNEigbC=> MWjpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MYWyOlE{QDZ5MR?=
OVCAR-5 NWrQWVBnS2WubDDWbYFjcWyrdImgRZN{[Xl? MmLCNE03OCEQvF2= M2eyVVI1NzR6L{eyJIg> M3\Ce4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NVPNfZhwOjZzM{i2O|E>
SK-OV-3 MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlLPNE0yODBizszN Mn70NlQwPDhxN{KgbC=> M4\jcolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NEPxXmYzPjF|OE[3NS=>
PA-1 M2X1e2Z2dmO2aX;uJGF{e2G7 M{nBUlExKM7:TdMg NH;QSVkzPGh? MkT2eJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz MmK2NlYyOzh4N{G=
OVCAR-5 NU\4SJJ6TnWwY4Tpc44hSXO|YYm= MmrxN|Ah|ryP MojiOFhp MmrOeJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz MUGyOlE{QDZ5MR?=
SK-OV-3 MXjGeY5kfGmxbjDBd5NigQ>? NYDtR2hnPTBizszN M4KzZlk3KGh? M3Kwe5RzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> M1rwPVI3OTN6Nkex
PA-1 M2DXfWZ2dmO2aX;uJGF{e2G7 NVnVNnhvOTBizszNxsA> NEe1Xmw1QGh? NV\NO45yfXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| M3TJeFI3OTN6Nkex
OVCAR-5 M{jrbGZ2dmO2aX;uJGF{e2G7 MYCzNEDPxE1? NHjmbmE1QGh? Ml7xeZAuemWpdXzheIV{KHSqZTDzeJJme3NibHnnZY5leyCob4KgUmsh[2WubD3hZ5RqfmG2aX7nJJJm[2WydH;yd{BidmRiVGLBTWwhemWlZYD0c5J{ MUmyOlE{QDZ5MR?=
SK-OV-3 MkTPSpVv[3Srb36gRZN{[Xl? MkXxOVAh|ryP M4jQXVk3KGh? NUHkT5pOfXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| NXni[ZF4OjZzM{i2O|E>
PA-1 M3HDR2Z2dmO2aX;uJGF{e2G7 NUT3OpdCOTBizszNxsA> NX\IZmZ2OjSq NEXPSJNxem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> NHPr[ogzPjF|OE[3NS=>
OVCAR-5 M2Tjb2Z2dmO2aX;uJGF{e2G7 NVPBWWJQOjBizszNxsA> M4[2V|I1cA>? NXOwfWM3eHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM> NHr2RnQzPjF|OE[3NS=>
SK-OV-3 MlzSSpVv[3Srb36gRZN{[Xl? MYe1NEDPxE4EoB?= M{fsO|Q5KGkEoB?= MXTwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= NHPxe2gzPjF|OE[3NS=>
CT26  NVHiSZdETnWwY4Tpc44hSXO|YYm= M2LCWFQhdU1? MlrHOFghcMLi M3TVXYlv\HWlZYOgZZV1d3CqYXf5 M4P2c|I3OTN5MEGy
CT26  M4G1NWZ2dmO2aX;uJGF{e2G7 NETldVM1KG2P M1jNSVQ5KGkEoB?= M2\x[Ylv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdHNib3[gZZV1d3CqYXf5MZJmdGG2ZXSgdJJwfGWrboOsJJN2[2hiYYOgUGM{NUmLLDDC[YNtcW5zIHHu[EBCXEd3 Mne3NlYyOzdyMUK=
CT26  NH3zNIZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3PPdVQhdU1? Mon5OFghcMLi NFHHd2ll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgeI8hPTNwMjW= MUiyOlE{PzBzMh?=
BE NUn2dlBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\wflVKSzVyPUOuN|Mh|ryP M4ixcFI3ODJ|MEi1
Colo205 M1\P[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHJ[ZdKSzVyPUOuN|Mh|ryP NV7QNJF4OjZyMkOwPFU>
DLD1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Hqe2lEPTB;Mj6wNUDPxE1? MYGyOlAzOzB6NR?=
HT29 Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFyxfpVKSzVyPUKuOlkh|ryP MYWyOlAzOzB6NR?=
HCT15 NGXCTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVztOotuUUN3ME2xMlQ{KM7:TR?= NIjEeZIzPjB{M{C4OS=>
HCT116 M4HtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwMESg{txO NYn6eJBtOjZyMkOwPFU>
HCT116p53- MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwMEig{txO MXyyOlAzOzB6NR?=
KM12 M{n1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLzTWM2OD12LkO3JO69VQ>? M{X4XlI3ODJ|MEi1
LoVo Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjycXJvUUN3ME2xMlIh|ryP M2O0eFI3ODJ|MEi1
RKO NHvGbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTuTWM2OD1zLkKzJO69VQ>? NFf0OIszPjB{M{C4OS=>
SW480 M4nI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjV[GZKSzVyPUKuPFYh|ryP MoXyNlYxOjNyOEW=
SW620 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TGXWlEPTB;Mz62PEDPxE1? M4HlU|I3ODJ|MEi1
MC38 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJ|IN88UUDDuSB{ M3HyR|I3ODB2MEi0
HT29 NWO3cVhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTZ|IN88UUDDuSBzOB?= NYLsbnViOjZyMESwPFQ>
DLD-1 NIS2eZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPjTWM2OD1|Mj6yJO69VQ>? M{PlelI3ODB|MEi1
HT-29 NGKxR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:xd5dKSzVyPUO1MlYh|ryP M3P4[FI3ODB|MEi1
SiHa NVjVbG1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO1TWM2OD1yLkigxtEhOC5zIN88US=> MmTyNlU5ODFyMEe=
S3 M1Xtd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLQTWM2OD13Mz61JOKyKDFwNTFOwG0> NYnDSHYyOjV6MEGwNFc>
AGS M2DpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;kcm5vUUN3ME2xNE43KM7:TR?= NFW2W2UzPTd6OUC1Oy=>
MKN-45 NUHyZVM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XwXGlEPTB;MUSuNEDPxE1? MYSyOVc5QTB3Nx?=
TMK-1 M1jn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\GNW9YUUN3ME2yNk43KM7:TR?= NEDYeIczPTd6OUC1Oy=>
SCM-1 NX3SS2VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1viVmlEPTB;MUeuOUDPxE1? MnrpNlU4QDlyNUe=
HCT-15 NF3We2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRThwNkSg{txO NFW5bFYzPTd4MUS3PS=>
DiFi M1zKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvBcmtyUUN3ME2xNE46PSEQvF2= MlHnNlU4PjF2N{m=
DLD-1 NGnDXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvRTWM2OD16Lk[1JO69VQ>? NHW0WJkzPTd4MUS3PS=>
COLO-320DM M3T3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTVwM{ig{txO M1vHNVI2PzZzNEe5
SNU-175 NXm2dGtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTBTWM2OD1zLkWxJO69VQ>? M{nWSlI2PzZzNEe5
HT-29 NGHY[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;ITWM2OD13LkKyJO69VQ>? MVmyOVc3OTR5OR?=
SW620 MkHNSpVv[3Srb36gRZN{[Xl? MX2xNQKBkcL3Zz;tcC=> NVPVZXVZOjUkgJno NH7pZmZqdmO{ZXHz[ZMhVEN|LVnJJIFk[3WvdXzheIlwdiCjbnSg[IVkemWjc3XzJHA3OiCneIDy[ZN{cW:w MYWyOVc1QTR{MB?=
SW480 NYD2UJZNTnWwY4Tpc44hSXO|YYm= M3n4fVEx6oDLwsXnM41t MUKyOQKBkWh? MmXwbY5kemWjc3XzJGxEOy2LSTDhZ4N2dXWuYYTpc44h[W6mIHTlZ5Jm[XOnczDQOlIh\XiycnXzd4lwdg>? NGLsWIUzPTd2OUSyNC=>
SW620 MWnGeY5kfGmxbjDBd5NigQ>? MkOyNVDjiIoEtXevcYw> MW[yOQKBkWh? MUflcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh? NX3lWHBrOjV5NEm0NlA>
SW480 NHv0W3ZHfW6ldHnvckBCe3OjeR?= MVixNQKBkcL3Zz;tcC=> NGPpOGIzPOLCiXi= M{LIToVvcGGwY3XzJINmdGy3bHHyJIF2fG:yaHHnbYMh\my3eB?= NIq2NJEzPTd2OUSyNC=>
A549 Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLqTWM2OD13LkigxtEhOC54IN88US=> NES4WHUzPTZ{NUK0Ny=>
A549/CDDP Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTF6Lk[gxtEhOS5{IN88US=> NF:1boMzPTZ{NUK0Ny=>
Panc-1 MlzER4VtdCCYaXHibYxqfHliQYPzZZk> MkDGNlUwPTBizszN MmnjNlQwPDhiaB?= NFnpV|ZqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? MXqyOVQ1PDlzNB?=
MIAPaCa-2 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4TyUlI2NzVyIN88US=> NYm4c4pFOjRxNEigbC=> MXXpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> MXmyOVQ1PDlzNB?=
SW1990 MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVnUSG5HOjVxNUCg{txO NWDGUIlsOjRxNEigbC=> M1r1TYlvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? NHXsfY8zPTR2NEmxOC=>
HPDE NEPpbnRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MoHENlUwPTBizszN MYqyOE81QCCq Ml;TbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MX2yOVQ1PDlzNB?=
Panc-1 M1TjbmFxd3C2b4Ppd{BCe3OjeR?= NWD0PWRZOjYkgJpCuW0> M1HlVlI1KGh? MnzqbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? MUmyOVQ1PDlzNB?=
MIAPaCa-2 NU[1U5JPSXCxcITvd4l{KEG|c3H5 NHPPZVgzPeLCidM1US=> M{fIfVI1KGh? MWfpcoR2[2W|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC NIHUT5MzPTR2NEmxOC=>
Panc-1 M3\MVmZ2dmO2aX;uJGF{e2G7 NHrNVIQzPeLCidM1US=> MlPxNlQwPDhiaB?= NX7w[mlHcW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG|ZT2zxsA> NWPoNG9xOjV2NES5NVQ>
MIAPaCa-2 M{GzTWZ2dmO2aX;uJGF{e2G7 MWeyOgKBkcL3TR?= NVjpZ3VtOjRxNEigbC=> MX;pcoR2[2W|IHPs[YF3[WenIH;mJHBCWlBuIHPhd5Bie2VvOTygZ4F{eGG|ZT24JIFv\CClYYPwZZNmNTQEoB?= MWSyOVQ1PDlzNB?=
SW480 NYfpU3NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDxO|IhcMLi M1;y[2lEPTB;MUCuO:KyOi5{NjFCuYcwdUx? MYWyOVM3ODZ|MR?=
HCT116  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPTO2V6PzJiaNMg M{TqcmlEPTB;Nj6yN:KyOC55NTFCuYcwdUx? NVLwcFJ{OjV|NkC2N|E>
COC1 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TDe2lEPTB;NE[uNlDDqMLzwrCzMlE1KM7:TR?= NF;VWHQzPTNyN{S0PC=>
SGC7901 NF63SFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jmc2lEPTB;MkGuO|PDqMLzwrCzMlA5KM7:TR?= NHTPS48zPTNyN{S0PC=>
A549 Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrQdIJKSzVyPUWxMlA5yqEEsdMgNVAvQTZizszN M3rwelI2OzB5NES4
HepG2 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF2LkK0xsDDucLiMT64NkDPxE1? MlOzNlU{ODd2NEi=
MCF-7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnTT21KSzVyPUG0MlI1yqEEsdMgNU45OiEQvF2= Mm[xNlU{ODd2NEi=
HCT-116 M2fCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTZwMkVCpOKyyqB{Lkm3JO69VQ>? NU\Eb5R4OjV|MEe0OFg>
HT-29 NVvSe2U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRjVyIN88US=> Mnv5NlU{ODd2NEi=
HEK293 MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe2[4pKSzVyPUiuPFLDqMLzwrC1MlU6KM7:TR?= MkDoNlU{ODd2NEi=
HUVEC M3K5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFzLkOwxsDDucLiMT6wNkDPxE1? NWD5cHZROjV|MEe0OFg>
SW480 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjQOJplOcLizszN MWWwMVczKGh? NUfxVlNrcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? M3jmblI1QTl5NEWx
HT-29 MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILTNZcyyqEQvF2= MnvXNE04OiCq NFXhSIxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? NX7FfnZ5OjR7OUe0OVE>
HCT116 MlH4SpVv[3Srb36gRZN{[Xl? MXuyM|UhyrWP NG\CPGQzPC92ODDo NUnQRnFLe3WycILld5NmeyC|dYL2bZZqdiCvUl7BJIV5eHKnc4Ppc44> NHnUcpAzPDd4MUSxNS=>
SW480  MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrGbWE1QCCqwrC= NHrpXXZKSzVyPUKwMlghfWdxbVy= MX:yOFczODZ5NR?=
SW620 NXThTXY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PIUVExNTdyIH3nM2w> MoXvNlQwPDhxN{KgbC=> M3XHV4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NVrLNYdTOjR4NE[zNFU>
Caco2  MlrxSpVv[3Srb36gRZN{[Xl? MnTMN|DDqM7:TR?= MX2yOEBp MVjEUXNQ NXTnR4YxcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBJVy1zLDDBT3IySyxiYX7kJG5SVzF? MYmyOFU2PjRzNR?=
Caco2  MXrGeY5kfGmxbjDBd5NigQ>? NHPnUog{NzFyL{OwJO69VQ>? NWrx[VRQOTZiaB?= MY\EUXNQ NWDYZYQ5cW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQVvSNWMyNCCQUV:xMEBJVy1zLDDNVnAzNMLiYX7kUXJRO8LiZH;z[U1l\XCnbnTlcpRtgQ>? NFLvUoMzPDV3NkSxOS=>
Caco2 M4rmRmZ2dmO2aX;uJGF{e2G7 MY[zNE8yODEEoN88US=> MWKxOuKhcA>? NGTFWYtFVVOR MkXqZYN1cX[jdHXzJG5z\jJ? MoTWNlQ2PTZ2MUW=

... Click to View More Cell Line Experimental Data

In vivo A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Formulation: Water solution
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage powder
in solvent
Synonyms L-OHP

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03422523 Recruiting Diffuse Large B Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma University Hospital Southampton NHS Foundation Trust|Hoffmann-La Roche May 9 2018 Phase 2
NCT03221426 Recruiting Gastric Cancer|Gastroesophageal Junction Cancer Merck Sharp & Dohme Corp. October 9 2017 Phase 3
NCT03607656 Recruiting Gastric Cancer Stage IIIB|Gastric Cancer Stage IIIC Shanghai University of Traditional Chinese Medicine|RenJi Hospital|Jiangsu Province Hospital of Traditional Chinese Medicine June 8 2018 Phase 2|Phase 3
NCT01928290 Active not recruiting Stomach Neoplasms|Esophageal Neoplasms Washington University School of Medicine November 8 2013 Phase 2
NCT03615326 Not yet recruiting Gastric Neoplasms|Gastroesophageal Junction Adenocarcinoma Merck Sharp & Dohme Corp. September 7 2018 Phase 3
NCT03321643 Recruiting Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma National Cancer Institute (NCI) March 7 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID